查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032944

亨廷頓舞蹈症治療市場規模、佔有率、趨勢和預測：按類型、藥物類型、年齡、分銷管道、最終用戶和地區分類，2026-2034 年

Huntington's Disease Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Age, Distribution Channel, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2025年全球亨廷頓舞蹈症治療市場規模為6.793億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以16.66%的複合年成長率成長，到2034年達到28.292億美元。目前，北美市場佔據主導地位，預計2025年市佔率將達到40.0% 。神經退化性疾病研發投入的增加是推動市場成長的主要動力。此外，人們對該疾病的認知不斷提高以及診斷設備的持續創新也加速了市場成長。同時，人們對該疾病相關未滿足需求的認知不斷提高，也對亨廷頓氏症治療市場佔有率的擴大起到了重要作用。

亨廷頓舞蹈症治療市場正經歷顯著成長，這得益於多種顛覆性趨勢和促進因素的推動，這些趨勢和因素正在積極重塑其市場結構。生物製藥公司越來越關注開發疾病修正治療，而不僅僅是緩解症狀的療法。這一趨勢的驅動力在於基因標靶技術的廣泛應用，包括反義寡核苷酸和核糖核酸（RNA）干擾，這些技術為改變疾病進程提供了新的思路。同時，臨床研究機構正與製藥公司合作，縮短臨床實驗週期，加速創新週期。

隨著研究機構、製藥公司和監管機構致力於將有效治療方法推向市場，美國亨廷頓舞蹈症治療市場正在改變。生技公司正加大對創新基因和RNA療法的投資，旨在延緩或阻止疾病進展。目前，許多州正在協調進行臨床試驗，學術機構和專科神經科診所正攜手合作，以快速測試新治療方法。這種創新浪潮正使美國成為亨丁頓舞蹈症研究的領先中心。公眾意識宣傳活動和患者支持活動正在增加早期診斷的機會，並擴大患者參與臨床研究的範圍。 2024年，亨廷頓病協會（HDSA）啟動了線上舉措“#letstalkabouthd”，以此紀念亨廷頓病宣傳月32週年。

亨廷頓舞蹈症治療市場趨勢：

擴大神經退化性疾病領域的研究與發展活動

針對神經退化性疾病的研發工作正不斷加強，推動市場成長。製藥公司、生技公司和學術機構正投入巨資，致力於闡明亨丁頓舞蹈症的遺傳和分子機制。研究人員正在開發前沿策略，例如利用反義寡核苷酸進行基因靜默療法、利用叢集規律性殘基間隔短重複序列（CRISPR）進行基因編輯以及幹細胞衍生的再生機制。所有這些努力都有助於建立一個健康的治療方法線，其中許多療法正處於臨床實驗階段，並已進入臨床試驗階段，這使得亨廷頓病治療市場的前景一片光明。來自政府和私人資金的投資也不斷增加，加強了公私合作關係。隨著我們對該疾病病理學的理解不斷加深，新的治療標靶不斷被發現，拓展了治療領域。 2025年，羅徹斯特大學醫學中心的一項新研究表明，成年人的大腦可以產生新的神經元，這些神經元可以整合到重要的運動迴路中。這項研究表明，激活大腦的自然功能可以幫助修復亨廷頓病和其他疾病中受損的神經網路。

人們對亨廷頓舞蹈症的認知不斷提高，診斷技術也取得了進展。

亨廷頓舞蹈症認知度的提高以及診斷設備的持續創新正在推動亨廷頓舞蹈症治療市場的成長。公共衛生工作的加強、宣傳活動的開展以及教育舉措的推進，提高了患者、看護者和醫療服務提供者對該疾病的認知，從而促進了早期診斷和早期療育。同時，診斷能力也得到了提升，更高品質、更精準的基因檢測和神經影像技術相繼問世。這些進步使醫生能夠更早確診，從而實現更及時的治療和參與臨床試驗。製藥公司也在進行宣傳活動，向患者和醫生介紹新的治療方法，從而提高了治療的可及性。此外，用於識別無症狀攜帶者的預測性檢測為早期治療提供了可能，促使人們轉向預防性護理和疾病修正治療。各公司正大力投資研發高效的神經影像設備，以提高疾病檢測的準確性。例如，2025年，Hyperfine公司宣布與NVIDIA建立策略合作夥伴關係，旨在透過其Swoop®系統革新腦影像技術。 Swoop®系統是首個獲得FDA已通過核准的可攜式磁振造影（MRI）腦部造影系統，並搭載了人工智慧技術。此次合作將利用NVIDIA的人工智慧和高速運算技術，加速Hyperfine的可攜式成像技術，使磁振造影（MRI）在全球範圍內更快、更智慧、更普及。

擴大監管支持並加速核准流程

主要市場的監管機構正在加強對亨廷頓病治療藥物研發和商業化的支持。衛生部門日益認知到亨廷頓舞蹈症領域尚未滿足的醫療需求，並向有前景的候選藥物授予孤兒藥、快速通道和突破性療法等認定。這些監管獎勵正在縮短研發週期、降低成本，並刺激生物製藥公司的投資。監管機構也鼓勵與臨床試驗贊助者進行公開對話，以簡化臨床試驗設計並關注與患者預後相關的終點指標。這有助於促進創新，並創造一個患者能夠快速獲得新治療方法的環境。同時，上市後數據和真實世界數據也擴大被用於支持監管決策。因此，監管環境正在透過降低准入門檻，積極塑造亨廷頓氏症治療產業的發展路徑。 2024年，瑞士製藥公司諾華向PTC Therapeutics（PTCT.O）支付了高達29億美元的費用，用於購買一種用於治療亨廷頓病這種神經系統疾病的有前景的實驗性療法。這種代號為「PTC518」的藥物正處於治療這種罕見疾病的中期臨床試驗階段，這種疾病影響著美國約30,000人。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球亨廷頓舞蹈症治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 症狀治療
  • 疾病修正治療

第7章 市場區隔：依藥物類型分類

  • 已通過核准藥物
    • 主要部分
      • Tetrabenazine
      • Deutetrabenazine
  • 仿單標示外用藥

第8章 市場區隔：依年齡層別分類

  • 50歲以下
  • 超過50歲

第9章 市場區隔：依分銷通路分類

  • 藥局和零售藥房
  • 醫院藥房
  • 網路藥房

第10章 市場區隔：依最終用戶分類

  • 醫院
  • 居家照護
  • 專科診所
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章：促進、抑制與機遇

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AOP Health
    • Apotex Inc.
    • Dr. Reddy's Laboratories Ltd.
    • H. Lundbeck A/S
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Prilenia Therapeutics
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
    • Vaccinex Inc.
Product Code: SR112026A6883

The global Huntington's disease treatment market size was valued at USD 679.3 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 2,829.2 Million by 2034, exhibiting a CAGR of 16.66% from 2026-2034. North America currently dominates the market, holding a market share of 40.0% in 2025 . An increase in research and development (R&D) efforts directed towards neurodegenerative conditions is impelling the market growth. This, along with the heightened awareness and continuous innovations in diagnostic equipment, is propelling the market growth. Apart from this, the rising focus on recognizing the unmet medical need in disease is playing a major role in expanding the Huntington's disease treatment market share.

The treatment market for Huntington's disease is witnessing significant growth as various disruptive trends and drivers are working towards actively redefining its landscape. Biopharmaceutical firms are becoming increasingly interested in developing disease-modifying therapies, looking beyond symptomatic treatment. This trend is driven by the rising utilization of gene-targeting technologies, including antisense oligonucleotides and ribonucleic acid (RNA) interference, which are bringing new ideas for modifying the course of the disease. Concurrently, clinical research organizations are collaborating with pharma companies to speed up trial timelines, and this is contributing to faster cycles of innovation.

The United States Huntington's disease treatment market is transforming as research centers, drug makers, and regulatory bodies are heightening their focus to bring effective treatments to the market. Biotech companies are investing more in innovative gene therapies and RNA treatments intended to slow down or stop disease progression. Clinical trials are now being coordinated in many states, with academic centers and specialty neurology clinics working together to try new therapies under expedited timelines. This explosion of innovation is making the US a major center for research into Huntington's disease. Public awareness campaigns and patient advocacy initiatives are increasing early diagnosis and patient engagement in clinical research. In 2024, the Huntington's Disease Society of America (HDSA) celebrated its 32nd year of Huntington's disease month with the launch of an online initiative named #letstalkabouthd.

HUNTINGTON'S DISEASE TREATMENT MARKET TRENDS:

Increasing Research and Development (R&D) Activities in Neurodegenerative Disorders

Rising research and development (R&D) efforts that are directed towards neurodegenerative conditions is impelling the market growth. Pharmaceutical, biotechnology organizations, and academies are stepping up efforts in funding to investigate the genetic and molecular underpinnings of Huntington's disease. Researchers are formulating cutting-edge strategies such as gene silencing therapies like antisense oligonucleotides, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing, and stem cell-derived regenerative mechanisms. All these efforts are contributing to a healthy pipeline of investigational therapies, most of which are moving into advanced stages of clinical trials, thereby offering a favorable Huntington's disease treatment market outlook. Investment from the government and private funding agencies is also pouring in, increasing collaborative efforts between the public and private sectors. With the rise in understanding of the disease pathophysiology, new targets are being identified for therapies, thus broadening the horizon of treatment. In 2025, new research by the University of Rochester Medical Centre revealed that the brain of an adult can produce new neurons that incorporate into essential motor circuits. The research illustrates that activating natural brain functions can aid in fixing harmed neural networks in Huntington's disease and other disorders.

Growing Awareness and Diagnostic Advancements in Huntington's Disease

Increasing awareness and continuous innovations in diagnostic equipment are propelling the Huntington's disease treatment market growth. Public health efforts, advocacy organization actions, and enhanced educational efforts are raising awareness among patients, caregivers, and providers, resulting in earlier diagnosis and intervention. Concurrently, diagnostic capacity is improving, with higher-quality genetic testing and neuroimaging methods being available and precise. These advances are allowing physicians to verify diagnoses earlier, enabling more timely treatment and trial entry. Pharmaceutical firms are also launching educational initiatives to inform patients and physicians about new therapies, thus enhancing treatment take-up. Additionally, the detection of pre-symptomatic carriers by predictive testing is opening up possibilities for early therapy, which is bringing a shift towards preventive and disease-modifying therapies. Companies are investing heavily in developing effective neuroimaging devices to improve the detection of diseases. For instance, in 2025, Hyperfine, Inc. revolutionized brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system powered by AI, the Swoop(R) system, and declared a strategic partnership with NVIDIA . The partnership utilizes NVIDIA AI and accelerated computing to accelerate Hyperfine portable imaging technology, enabling brain magnetic resonance imaging (MRI) faster, smarter, and more accessible globally.

Expansion of Regulatory Support and Accelerated Approval Pathways

Regulatory agencies across key markets are expanding support for the development and commercialization of Huntington's disease therapies. Health authorities are increasingly recognizing the unmet medical need in Huntington's disease and are granting designations such as orphan drug, fast track, and breakthrough therapy to promising candidates. These regulatory incentives are shortening development timelines, reducing costs, and encouraging investment from biopharma companies. Agencies are also facilitating open dialogue with sponsors to streamline clinical trial design and address endpoints relevant to patient outcomes. This is fostering an environment conducive to innovation and quicker patient access to novel therapies. Simultaneously, post-marketing commitments and real-world evidence are increasingly being leveraged to support regulatory decisions. The regulatory landscape is thus actively shaping the trajectory of the Huntington's disease treatment industry by reducing barriers to entry. In 2024, Swiss pharmaceutical company Novartis paid as much as $2.9 billion for PTC Therapeutics' (PTCT.O), promising experimental medicine for a neurological condition known as Huntington's disease. The medicine, code-named "PTC518," was undergoing a mid-stage trial for the rare condition that strikes around 30,000 individuals in the US.

HUNTINGTON'S DISEASE TREATMENT INDUSTRY SEGMENTATION:

Analysis by Type:

  • Symptomatic Treatment
  • Disease-modifying Therapies

Symptomatic treatment stands as the largest component in 2025, holding around 69.8% of the market. Symptomatic treatment for Huntington's disease is still taking center stage in the therapeutic picture, as it continues to help manage the broad range of physical, cognitive, and psychiatric symptoms attendant to the disease. Physicians are prescribing increasing amounts of antipsychotic medications, antidepressants, and mood stabilizers to help manage behavioral disruptions like depression, anxiety, and irritability. Meanwhile, clinicians are using treatments of motor symptoms such as tetrabenazine and deutetrabenazine in managing involuntary movement, including chorea. These medicines are being routinely improved for tolerability and for longer-term safety. Multidisciplinary team care is also incorporating non-medicine interventions in the form of physical therapy, occupational therapy, and speech therapy that are adding to patients' functional independence as well as enhancing the quality of their lives.

Analysis by Drug Type:

  • Approved Drugs
    • Tetrabenazine
    • Deutetrabenazine
  • Off-label Drugs

Approved drugs (tetrabenazine and deutetrabenazine) lead the market with around 60.0% of market share in 2025. Approved drugs like tetrabenazine and deutetrabenazine are still making up the mainstay of pharmacological management of Huntington's disease. These drugs are being increasingly prescribed by neurologists to mitigate involuntary movements by regulating dopamine activity in the brain. Tetrabenazine, the first FDA-approved medication for Huntington's chorea, is being used for its effectiveness in decreasing motor symptoms. Apart from this, deutetrabenazine is being more widely accepted as a safer and more tolerable option because of its altered pharmacokinetic profile, which is making less frequent dosing and better patient compliance possible. Pharmaceutical manufacturers are investing in post-marketing research and real-world evidence gathering to determine long-term safety and efficacy of these medications. Healthcare professionals are actively monitoring treatment response and dose adjustments to maximize therapeutic benefits.

Analysis by Age:

  • Below 50 Years
  • Above 50 Years

Below 50 years leads the market with 54.8% of market share in 2025. Treatment for individuals aged below 50 years is facing high demand with more cases of early-onset being diagnosed using genetic testing and enhanced clinical suspicion. Healthcare professionals are diagnosing symptomatic and pre-symptomatic individuals aged below 50 years with increased frequency, which enables earlier treatment and management. Younger patients are now actively enrolling in clinical trials and experimental treatment protocols, furthering the development of individualized therapeutic strategies. Researchers are concentrating efforts on developing treatment plans for this population, acknowledging that early intervention can slow the progression of symptoms and enhance long-term outcomes. Pharmaceutical firms are developing targeted treatments that meet the particular neurological and functional requirements of patients under the age of 50, who are still working and maintaining family responsibilities.

Analysis by Distribution Channel:

  • Drug Stores and Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Drug stores and retail pharmacies lead the market with 40.5% of market share in 2025. They are increasingly becoming essential in the dispensing of treatments for Huntington's disease, especially approved symptomatic medications such as tetrabenazine and deutetrabenazine. The retail pharmacies are increasing their stock to include specialized medications for neurodegenerative disorders, making them available to patients on a consistent basis in both suburban and urban regions. Pharmacists are playing an active role in patient education through counseling on dosing, side effects, and medication adherence, which is improving treatment outcomes and patient activation. Retail chains are also collaborating with drug firms and healthcare providers to streamline the supply chain, promoting timely delivery and minimizing stockouts of highly demanded drugs. Furthermore, most drug stores are embracing digital platforms and online prescription services, providing patients with easy access to their medications via home delivery or appointment-based pickups.

Analysis by End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Hospitals are serving as the primary centers for diagnosis, treatment initiation, and ongoing management of Huntington's disease. These facilities are equipped with advanced diagnostic tools and multidisciplinary care teams, including neurologists, psychiatrists, genetic counselors, and rehabilitation specialists. Inpatient services and integrated care models allow hospitals to manage severe or complex cases, including those involving psychiatric crises or complications from motor dysfunction.

Homecare is emerging as a preferred option for patients in advanced stages of Huntington's disease, offering comfort, convenience, and personalized support. Caregivers and visiting healthcare professionals are administering prescribed medications, managing mobility issues, and assisting with daily living activities. The growing availability of home-based rehabilitation services, including physical and speech therapy, is helping to maintain quality of life for patients outside of clinical settings.

Specialty clinics dedicated to neurodegenerative disorders are playing a crucial role in providing focused and continuous care for Huntington's disease patients. These clinics offer specialized expertise, enabling precise diagnosis, tailored treatment planning, and close monitoring of disease progression. By integrating neurology, psychiatry, and rehabilitation services under one roof, specialty clinics are streamlining care and improving patient outcomes.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America holds 40.0% of the market share. North American Huntington's disease treatment sector is growing aggressively based on improvement in research, facilitating regulatory environment, and improving awareness of the disease. North American pharmaceutical players invest heavily in making gene therapy products and disease-altering medications by continuously performing several clinical trials throughout the United States and Canada. Scholarly research organizations and biotechnology companies are joining forces to determine new targets of therapy and improve current treatment methods. These alliances are speeding the rate of innovation and broadening the treatment pipeline. At the same time, regulatory bodies like the U.S. Food and Drug Administration (FDA) are granting fast-track and orphan drug designations to potential candidates, facilitating faster market access. Awareness groups are mounting public education campaigns, which are producing earlier diagnoses and enhanced patient involvement in treatment and clinical trials. As per Huntington's disease treatment market report, healthcare systems are integrating telemedicine and digital health solutions to facilitate long-term disease management, thus consolidating market growth.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HUNTINGTON'S DISEASE TREATMENT MARKET ANALYSIS

The United States holds around 90% share in North America. The growing incidence of Huntington's disease in the United States has significantly contributed to the increased adoption of Huntington's disease treatment. For instance, there are approximately 41,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease. With more individuals being diagnosed, there is a growing need for therapies aimed at managing symptoms and improving quality of life. This has led to advancements in treatment options, including the development of specialized medications and therapies. The rising awareness about Huntington's disease, coupled with the increasing number of healthcare facilities focusing on neurology, has further fueled treatment adoption. Additionally, ongoing research and clinical trials have played a vital role in enhancing treatment modalities, making them more accessible to patients. As the number of diagnoses is rising, the demand for effective treatments is presumed to keep growing.

ASIA PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET ANALYSIS

In the Asia-Pacific region, the growing number of hospital pharmacies has been a significant factor in the increased adoption of Huntington's disease treatments. For instance, the Delhi Government, in India, developed an extensive public health infrastructure with 38 hospitals including six super specialty hospitals and eight autonomous hospitals. Hospital pharmacies play a crucial role in dispensing specialized medications that cater to the needs of patients suffering from neurodegenerative diseases like Huntington's disease. With the expansion of healthcare infrastructure and the increased capacity of hospital pharmacies, the availability of advanced treatments has been improved. This growth in hospital pharmacies is accompanied by an increase in awareness about Huntington's disease and a shift toward more effective treatment options. Moreover, as healthcare systems in the region continue to evolve, access to new therapies is becoming more widespread, driving further adoption of Huntington's disease treatment.

EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET ANALYSIS

In Europe, the growing geriatric population has been a primary driving factor behind the rising adoption of Huntington's disease treatment. According to Eurostat, in January 2024, the EU population was estimated at 449.3 million people, and more than one-fifth (21.6%) of it was aged 65 years and over. As the aging population increases, so does the prevalence of neurodegenerative diseases, including Huntington's disease. Older adults are at a higher risk of developing Huntington's, and as such, the demand for treatment options has surged. Healthcare providers are increasingly focusing on developing treatments tailored to the unique needs of elderly patients, ensuring better disease management and quality of life. Additionally, the expanding healthcare infrastructure and improved access to specialized care have played a key role in facilitating treatment adoption across Europe. The region's commitment to research and development in neurology further supports the growth of Huntington's disease treatment.

LATIN AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET ANALYSIS

In Latin America, the growing Huntington's disease treatment landscape is significantly shaped by the rising prevalence of neurodegenerative disorders, particularly those accompanied by neuropsychiatric symptoms (NPSs) such as depression, irritability, and psychosis. For instance, for instance, NPSs were highly prevalent in Hispanic populations with neurodegenerative disease; almost 34.3%, 56.1%, and 61.2% of the applicants with dementia, Parkinsonism, and PDD exhibited three or more NPSs, respectively. As awareness and diagnosis rates improve across the region, more patients are being identified at earlier stages, driving demand for advanced therapeutic approaches. Healthcare systems are increasingly prioritizing neurological care, and clinical trials focusing on NPS management are expanding. Pharmaceutical companies are also investing in region-specific drug development and distribution. This growing attention is fostering a robust environment for Huntington's disease treatment adoption throughout Latin America.

MIDDLE EAST AND AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET ANALYSIS

In the Middle East and Africa, the growth of hospitals, homecare services, and specialty clinics has been crucial in driving the adoption of Huntington's disease treatment. According to the Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with a total number of licensed healthcare facilities up to 5,020 and commissioning 59,509 extremely efficient healthcare professionals, as of 2024. These healthcare providers are focusing on offering specialized care to patients with neurodegenerative disorders, including Huntington's disease. With a growing emphasis on improving healthcare infrastructure, patients now have better access to treatments tailored to their specific needs. Homecare services are also playing an important role in offering ongoing support for patients outside of traditional healthcare settings.

COMPETITIVE LANDSCAPE:

Market players are actively expanding their research portfolios and forming strategic collaborations to accelerate drug development. Biotechnology and pharmaceutical companies are investing in gene-editing technologies, RNA-targeting therapies, and neuroprotective agents to introduce more effective and durable treatment options. Many firms are entering licensing agreements and research partnerships with academic institutions and biotech startups to access novel platforms and expertise. Simultaneously, companies are initiating global clinical trials and seeking regulatory designations such as Orphan Drug and Fast Track to shorten development timelines. Marketing strategies are also shifting, with firms launching educational campaigns to raise awareness among healthcare providers and patients. As per the Huntington's disease treatment market forecast, these coordinated efforts are expected to reinforce competitive positioning while contributing to sustained innovation in the treatment landscape.

The report provides a comprehensive analysis of the competitive landscape in the Huntington's disease treatment market with detailed profiles of all major companies, including:

  • AOP Health
  • Apotex Inc.
  • Dr. Reddy's Laboratories Ltd.
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Prilenia Therapeutics
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vaccinex Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Huntington's Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Symptomatic Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Disease-modifying Therapies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Approved Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Tetrabenazine
      • 7.1.2.2 Deutetrabenazine
    • 7.1.3 Market Forecast
  • 7.2 Off-label Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age

  • 8.1 Below 50 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Above 50 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Drug Store and Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Hospital Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Homecare
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Specialty Clinics
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AOP Health
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
    • 16.3.2 Apotex Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 SWOT Analysis
    • 16.3.3 Dr. Reddy's Laboratories Ltd.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 H. Lundbeck A/S
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Hikma Pharmaceuticals PLC
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Lupin Limited
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Prilenia Therapeutics
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Sun Pharmaceutical Industries Limited
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Teva Pharmaceutical Industries Ltd.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Vaccinex Inc.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials

List of Figures

  • Figure 1: Global: Huntington's Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Huntington's Disease Treatment Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Huntington's Disease Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Huntington's Disease Treatment Market: Breakup by Age (in %), 2025
  • Figure 7: Global: Huntington's Disease Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Huntington's Disease Treatment Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Huntington's Disease Treatment Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Huntington's Disease Treatment (Symptomatic Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Huntington's Disease Treatment (Symptomatic Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Huntington's Disease Treatment (Disease-modifying Therapies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Huntington's Disease Treatment (Disease-modifying Therapies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Huntington's Disease Treatment (Approved Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Huntington's Disease Treatment (Approved Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Huntington's Disease Treatment (Off-label Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Huntington's Disease Treatment (Off-label Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Huntington's Disease Treatment (Below 50 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Huntington's Disease Treatment (Below 50 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Huntington's Disease Treatment (Above 50 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Huntington's Disease Treatment (Above 50 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Huntington's Disease Treatment (Drug Store and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Huntington's Disease Treatment (Drug Store and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Huntington's Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Huntington's Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Huntington's Disease Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Huntington's Disease Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Huntington's Disease Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Huntington's Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Huntington's Disease Treatment (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Huntington's Disease Treatment (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Huntington's Disease Treatment (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Huntington's Disease Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Huntington's Disease Treatment (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Huntington's Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: North America: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: North America: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: United States: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: United States: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Canada: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Canada: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Asia-Pacific: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Asia-Pacific: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: China: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: China: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Japan: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Japan: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: India: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: India: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: South Korea: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: South Korea: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Australia: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Australia: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Indonesia: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Indonesia: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Others: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Others: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Europe: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Europe: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Germany: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Germany: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: France: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: France: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: United Kingdom: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: United Kingdom: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Italy: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Italy: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Spain: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Spain: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Russia: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Russia: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Latin America: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Latin America: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Brazil: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Brazil: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Mexico: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Mexico: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Middle East and Africa: Huntington's Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Middle East and Africa: Huntington's Disease Treatment Market: Breakup by Country (in %), 2025
  • Figure 84: Middle East and Africa: Huntington's Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Global: Huntington's Disease Treatment Industry: Drivers, Restraints, and Opportunities
  • Figure 86: Global: Huntington's Disease Treatment Industry: Value Chain Analysis
  • Figure 87: Global: Huntington's Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Huntington's Disease Treatment Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Huntington's Disease Treatment Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Huntington's Disease Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Huntington's Disease Treatment Market Forecast: Breakup by Age (in Million USD), 2026-2034
  • Table 5: Global: Huntington's Disease Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Huntington's Disease Treatment Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Huntington's Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Huntington's Disease Treatment Market: Competitive Structure
  • Table 9: Global: Huntington's Disease Treatment Market: Key Players